166 related articles for article (PubMed ID: 9264323)
21. Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.
Oie S; Ono M; Fukushima H; Hosoi F; Yano H; Maruyama Y; Kojiro M; Terada T; Hirano K; Kuwano M; Yamada Y
Mol Cancer Ther; 2007 Aug; 6(8):2310-8. PubMed ID: 17699726
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
23. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.
Chéradame S; Etienne MC; Chazal M; Guillot T; Fischel JL; Formento P; Milano G
Eur J Cancer; 1997 May; 33(6):950-9. PubMed ID: 9291820
[TBL] [Abstract][Full Text] [Related]
24. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
25. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
26. Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Sakurai Y; Uraguchi T; Imazu H; Hasegawa S; Matsubara T; Ochiai M; Funabiki T
Gastric Cancer; 2004; 7(2):110-6. PubMed ID: 15224198
[TBL] [Abstract][Full Text] [Related]
27. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
[TBL] [Abstract][Full Text] [Related]
28. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs.
Davis ST; Joyner SS; Baccanari DP; Spector T
Biochem Pharmacol; 1994 Jul; 48(2):233-6. PubMed ID: 8053919
[TBL] [Abstract][Full Text] [Related]
29. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
30. Oral fluoropoyrimidines.
Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
[TBL] [Abstract][Full Text] [Related]
31. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
[TBL] [Abstract][Full Text] [Related]
32. Dual effects of folinic acid in 5-fluorouracil induced killing of human tumor cell lines in vitro.
Blomgren H; Edler D; Hallström M; Ragnhammar P
Anticancer Res; 1996; 16(5A):2713-7. PubMed ID: 8917376
[TBL] [Abstract][Full Text] [Related]
33. The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Yasumatsu R; Nakashima T; Uryu H; Masuda M; Hirakawa N; Shiratsuchi H; Tomita K; Fukushima M; Komune S
Oral Oncol; 2009 Feb; 45(2):141-7. PubMed ID: 18620897
[TBL] [Abstract][Full Text] [Related]
34. Biomodulation of 5-Fu cytotoxicity by folinic acid and its stereoisomers: in vitro experiments with different cell lines of prostatic cancer.
Breul J; Jakse G; Hartung R
Urol Res; 1995; 23(3):163-7. PubMed ID: 7483142
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
Takechi T; Fujioka A; Matsushima E; Fukushima M
Eur J Cancer; 2002 Jun; 38(9):1271-7. PubMed ID: 12044515
[TBL] [Abstract][Full Text] [Related]
36. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
van der Wilt CL; Pinedo HM; Smid K; Cloos J; Noordhuis P; Peters GJ
Semin Oncol; 1992 Apr; 19(2 Suppl 3):16-25. PubMed ID: 1532671
[TBL] [Abstract][Full Text] [Related]
37. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
[TBL] [Abstract][Full Text] [Related]
38. Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
Ueda M; Kitaura K; Kusada O; Mochizuki Y; Yamada N; Terai Y; Kumagai K; Ueki K; Ueki M
Jpn J Cancer Res; 2000 Nov; 91(11):1185-91. PubMed ID: 11092985
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
40. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
Etienne MC; Chéradame S; Fischel JL; Formento P; Dassonville O; Renée N; Schneider M; Thyss A; Demard F; Milano G
J Clin Oncol; 1995 Jul; 13(7):1663-70. PubMed ID: 7602356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
